<PAGE>
--------------------
--------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported):
March 23, 1998
PACIFIC PHARMACEUTICALS, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE
---------------------------
(State or other jurisdiction of incorporation)
0-14838 36-3258753
------------------------ ----------------------
(Commission File Number) (IRS Employer Identification Number)
6730 MESA RIDGE RD.
SUITE A
SAN DIEGO, CALIFORNIA 92121
------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (619) 550-3900
--------------
<PAGE>
Item 5. Other Events.
News release dated March 23, 1998, announcing that the Company signed a
worldwide exclusive license for O(6) Benzyl Guanine (BG), a series of related
compounds and technologies which enhance the effectiveness of a class of
currently used chemotherapeutic agents (O(6) alkylators). These technologies
are licensed to the Company from Pennsylvania State University on behalf of
itself, National Institutes of Health and other universities. Multiple Phase
I human clinical trials for the BG compounds being conducted at the
University of Chicago, Duke University Medical Center and Case Western
Reserve University are nearing completion in different cancer types,
including brain, colon and renal carcinoma.
The terms of the license agreement include payments for royalties, license
fees and milestone payments to be paid in cash or common stock of the
Company. Some of the cash and common stock payments are contingent upon the
achievement of certain milestones in connection with the clinical development
and regulatory approval of the BG compounds.
Paramount Capital Investments, LLC ("Paramount") acted as financial advisor
to the Company in connection with the identification, negotiation and
consummation of the license and will receive a fee in cash and securities
vesting upon achievement of certain performance based events. Paramount is
affiliated with certain significant shareholders and a Director of the
Company.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) EXHIBITS. The following exhibit accompanies this Report:
Exhibit
Number Exhibit Description
------- -------------------
99.60 News release dated March 23, 1998, announcing that the Company
signed a worldwide exclusive license for O(6) Benzyl Guanine.
10.58 License Agreement dated March 17, 1998 between the Company and
Pennsylvania State University. Portions of the Exhibit have been
omitted pursuant to a request for confidential treatment.
10.59 Introduction Agreement dated February 12, 1998 between Paramount
Capital Investments LLC the Company. Portions of the Exhibit have
been omitted pursuant to a request for confidential treatment.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PACIFIC PHARMACEUTICALS, INC.
By: /s/ JAMES HERTZOG
------------------------
James Hertzog
Date: March 23, 1998 Controller-Principal Accounting Officer
3
<PAGE>
Index To Exhibits
-----------------
Exhibit Sequentially
Number Description of Exhibit Numbered Page
- ------- ---------------------- -------------
99.60 News release dated March 23,
1998, announcing that the
Company signed a worldwide
exclusive license for O(6) Benzyl
Guanine.
10.58 License Agreement dated March
17, 1998 between the
Company and Pennsylvania State
University. Portions of the
Exhibit have been omitted
pursuant to a request for
confidential treatment.
10.59 Introduction Agreement dated
February 12, 1998 between
Paramount Capital Investments
LLC the Company. Portions of
the Exhibit have been omitted
pursuant to a request for
confidential treatment.
4
<PAGE>
EXHIBIT 10.58
LICENSE AGREEMENT
This License Agreement (hereinafter referred to as this "Agreement"),
effective as of March 17, 1998 (the "Effective Date"), is entered into by and
between The Penn State Research Foundation (the "Licensor") and Pacific
Pharmaceuticals, Inc., a corporation duly organized and existing under the laws
of the State of Delaware (the "Company").
WHEREAS, the Licensor is the owners of U.S. Patent #'s 5,091,430,
5,358,952, 5,352,669, 5,525,606 and U.S. Patent Application # 08/620/969, filed
on March 25, 1996, U.S. Patent Application # 08/255/190, filed on June 7, 1994
and Divisional U.S. Patent Application # 08/661/923, filed on June 11, 1996
(divisional of U.S. Patent #5,525,606); and
WHEREAS, the Licensor represents that it has full power and authority
to enter into this Agreement on behalf of itself as well as the National
Institute of Health, Case Western Reserve University and ARCH Development
Corporation pursuant to the Interinstitutional Agreements attached hereto as
Exhibit B; and
WHEREAS, the Licensor may discover or develop additional intellectual
property, technical information or proprietary rights which may be subject to
the terms of this Agreement through the continuing work of Drs. Anthony Pegg,
Robert Moschel, Eileen Dolan and Stanton Gerson (collectively the "Principal
Investigators"), or such other principal investigators as may be designated by
the parties;
<PAGE>
WHEREAS, the Company now desires to obtain a license to the Invention,
under the initial application and to further developments arising out of the
Sponsored Research (as defined below), upon the terms and conditions hereinafter
set forth.
NOW, THEREFORE, it is agreed as follows:
ARTICLE 1 - DEFINITIONS
For the purposes of this License Agreement, the following words and
phrases shall have the following meanings:
1.1 The "Company" shall mean Pacific Pharmaceuticals, Inc., a
Delaware corporation.
1.2 "Affiliate" shall mean, with respect to any Entity (as
hereinafter defined), any Entity that directly or indirectly controls, is
controlled by, or is under common control with such Entity.
1.2.1 "Control" shall mean, for this purpose, direct or
indirect control of more than fifty percent (50%) of the voting securities of an
Entity or, if such Entity does not have outstanding voting securities, more than
50% of the directorships or similar positions with respect to such Entity.
1.2.2 "Entity" shall mean any corporation, association, joint
venture, partnership, trust, university, business, individual, government or
political subdivision thereof, including an agency, or any other organization
that can exercise independent legal standing.
2
<PAGE>
1.3 "Patent Rights" shall mean all U.S. and foreign patents and
patent applications set forth in Appendix I;
1.3.1 Any other United States and/or foreign, patent
applications and/or patents together with any and all patents issuing
thereon, including continuation, divisional and re-issue applications and
continuation-in-part applications and any United States or foreign patents
granted upon such applications, which (a) if practiced would infringe the
Patent Rights granted hereunder or (b) if patented, would fall within the
Patent Rights, and which are based upon inventions or improvements discovered
(x) by the Licensor through, by or under the direct or indirect direction of
the Principal Investigator of the Licensor or (y) by any other Principal
Investigator where such inventions or improvements involve the treatment of
cancer in humans.
1.3.2 Any other United States and/or foreign, patent
applications and/or patents together with any and all patents issuing
thereon, including continuation, divisional and re-issue applications and
continuation-in-part applications and any United States or foreign patents
granted upon such applications discovered by any Principal Investigator where
such inventions or improvements arise out of the performance of any Sponsored
Research, any and all of which shall be deemed added to Appendix I;
1.3.3 Any later-filed United States and/or foreign patent
applications based on the patent applications and/or patents listed in Appendix
I, or corresponding thereto, including any continuations, continuations-in-part,
divisional, reissues, reexaminations, or extensions thereof;
3
<PAGE>
1.3.4 Any United States and/or foreign patents issuing from
any of the foregoing; and
1.3.5 Any United States and/or foreign trademark applications
filed by or on behalf of the Licensor related to the Invention.
1.4 "Know-how" shall mean all tangible information (other than that
contained in the Patent Rights) whether patentable or not (but which has not
been patented) and physical objects that (a) if practiced, would infringe the
Patent Rights granted hereunder or (b) if patented, would fall within the Patent
Rights, in either case including but not limited to formulations, data, drawings
and sketches, designs, testing and test results (including pre-clinical research
data developed prior to the execution of this Agreement, which pre-clinical
research data shall include, without limitation, all pre-clinical research data
supporting the current Initial New Drug Application ("IND") filed by National
Cancer Institute ("N.C.I.")) and/or regulatory information of a like nature,
provided that any or all of the Co-owners have a right to disclose and license
such pre-clinical data and regulatory information to the Company. The term
"Know-how" shall expressly exclude (i) N.C.I. clinical data (the "N.C.I.
Clinical Data"), which shall be owned solely by the National Institute of Health
(the "N.I.H.") and (ii) all data developed under a Cooperative Research and
Development Agreement ("CRADA"), which shall be governed by the terms of such
CRADA.
1.5 "Licensed Product(s)" shall mean:
1.5.1 Any product which is covered in whole or in part by a
Valid Claim contained in the Patent Rights in the country in which the product
is made, used, leased or sold;
4
<PAGE>
1.5.2 Any product which is manufactured using a process which
is covered in whole or in part by a Valid Claim contained in the Patent Rights
in the country in which the process is used;
1.5.3 Any product which is used according to a method which
is covered in whole or in part by a Valid Claim contained in the Patent Rights
in the country in which the method is used.
1.6 "Licensed Process(es)" shall mean any process or method, which is
covered, in whole, or in part, by a Valid Claim contained in the Patent Rights
in the country in which the process or method is used.
1.7. "First Commercial Sale" means the initial transfer by or on
behalf of the Company, its Affiliate or its sublicensees of Licensed Products or
the initial practice of a Licensed Process by or on behalf of the Company, its
Affiliate or its sublicensees in exchange for cash or some equivalent to which
value can be assigned for the purpose of determining Net Sales.
1.8 "Net Sales" shall mean the total gross receipts for sales of
Licensed Products or practice of Licensed Processes by or on behalf of the
Company or any of its Affiliates, and from leasing, renting or otherwise making
Licensed Products available to others without sale or other dispositions,
whether invoiced or not, less only the sum of the following:
1.8.1 Usual trade discounts to customers;
1.8.2 Sales, tariff duties and/or use taxes directly imposed
and with reference to particular sales;
5
<PAGE>
1.8.3 Outbound transportation prepaid or allowed and
transportation insurance;
1.8.4 Amounts allowed or credited on returns;
1.8.5 Bad debt deductions actually written off during the
accounting period;
1.8.6 Sales commissions; and
1.8.7 Packaging and freight charges.
1.9 "Sponsored Research" shall mean any research conducted in the
laboratory of any the Inventors related to the Patent Rights and Know-how and
funded by the Company.
1.10 A "Valid Claim" shall mean any claim of a pending patent
application or an issued and unexpired patent.
1.11 "Co-owners" shall mean the Licensor, the National Institutes of
Health, Case Western Reserve University and the University of Chicago.
1.12 "Foreign Major Market Country" shall mean France, Germany, Italy,
the United Kingdom and Japan.
ARTICLE 2 - GRANT
2.1 The Licensor and the Co-owners hereby grant to the Company and
the Company accepts, subject to the terms and conditions of this Agreement a
sole and exclusive, worldwide license in all fields of use to practice under the
Patent Rights and to utilize the Know-how, and to make, have made, use, lease
and/or sell the Licensed Products and to practice the
6
<PAGE>
Licensed Processes, to the full end of the term for which the Patent Rights
are granted, unless sooner terminated as hereinafter provided.
2.2 Notwithstanding any other provision contained in this Agreement
(a) the Licensor retains an irrevocable, non-exclusive, non-transferrable,
royalty-free right to practice and have practiced or to use the Patent Rights
and Know-how solely for its internal, non-commercial use; (b) the government of
the United States retains an irrevocable, non-exclusive, non-transferrable,
royalty-free right to practice and have practiced or to use the Patent Rights
and Know-how for or on behalf of the United States or any foreign or
international organization under any existing treaty or agreement with the
United States for non-commercial use and (c) the United States shall retain such
other rights as it may have by law, rule or regulation.
2.3 To the Co-owners' knowledge and belief, the Co-owners have all
right, title, and interest in and to the Patent Rights, including exclusive,
absolute, irrevocable right, title and interest thereto, free and clear of all
liens, charges, encumbrances or other restrictions or limitations of any kind
whatsoever and to the Co-owners' knowledge and belief there are no licenses,
options, restrictions, liens, rights of third parties, disputes, royalty
obligations, proceedings or claims relating to, affecting, or limiting its
rights or the rights of the Company under this Agreement with respect to, or
which may lead to a claim of infringement or invalidity regarding, any part or
all of the Patent Rights and their use as contemplated in the underlying patent
applications as presently drafted.
7
<PAGE>
2.4 To the Co-owners' knowledge and belief there is no claim, pending
or threatened, of infringement, interference or invalidity regarding, any part
or all of the Patent Rights and their use as contemplated in the underlying
patent applications as presently drafted.
2.5 To the extent that any invention claimed under the Patent Rights
were developed with the use of federal funds, the Co-owners have made an
effective election of title thereto.
2.6 The Licensor has disclosed certain information to the Company
subject to the terms of the Confidentiality Agreement entered into prior to the
execution of this Agreement, some of which information may have been made
available to the public without restriction. Accordingly, within sixty (60)
days of the Effective Date, the Licensor shall provide the Company with a list
of all prior written publications, oral presentations and any other public
disclosure of the Patent Rights and/or information covered by Know-how, which
list shall be attached hereto as Schedule A.
2.7 The Licensor grants to the Company the right to grant sublicenses
to third- parties under the license granted hereunder, provided that the Company
shall remain bound by Section 4.1.2 hereof.
2.7.1 Within thirty (30) days after execution or receipt
thereof, as applicable, the Company shall provide the Licensor with a copy of
each sublicense issued hereunder and shall deliver copies of all royalty reports
received by the Company from such sublicensees.
8
<PAGE>
2.7.2 The Company shall use its reasonable best efforts to
include in any sublicense such language as the N.I.H. may require.
2.7.3 The Company shall use its reasonable best efforts to
require any sublicensee to agree to the diligence requirements set forth in this
Agreement.
2.7.4 Upon termination of this Agreement other than by
expiration in accordance with paragraph 8.6, any and all sublicenses shall
survive such termination.
ARTICLE 3 - DUE DILIGENCE
3.1 The Company shall use its reasonable best efforts to bring
Licensed Products or Licensed Processes to market through a thorough, vigorous
and diligent program for exploitation of the Patent Rights and Know-how and
continue active, diligent marketing efforts for Licensed Products or Licensed
Processes throughout the life of this Agreement generally as outlined in Exhibit
A and subject to paragraph 6.6 hereof.
3.2 The N.I.H. agrees to enter into good faith negotiations of a
CRADA pursuant to which, among other things, the N.I.H. shall make available to
the Company (x) all N.I.H. Clinical Data relating to any potential Licensed
Products or Licensed Processes developed or generated by the N.I.H. prior to the
date of the CRADA and (y) all subsequent data developed under such CRADA.
3.3 In order to facilitate the speedy development of the Patent
Rights, the Licensor hereby endeavors to transfer all Know-how to the Company
within thirty (30) days of execution of this Agreement.
9
<PAGE>
ARTICLE 4 - ROYALTIES AND OTHER CONSIDERATION
4.1 For the rights, privileges and license granted hereunder, the
Company shall pay to the Licensor as set forth below, and in accordance with the
provisions of Articles 4.4 and 4.5, to the end of the term of the Patent Rights
or until this License Agreement shall be terminated as hereinafter provided:
4.1.1 The Company shall pay to the Licensor non-refundable
semi-annual royalties in an amount equal to * percent (*%) of Net Sales by
the Company, or any Affiliate of the Company, of the Licensed Products or
Licensed Processes covered by at least one issued and unexpired claim under
the Patent Rights and * percent (*%) of Net Sales by the Company or any
Affiliate of the Company covered by pending patent claims.
4.1.2 The Company shall pay to the Licensor semi-annual
royalties in an amount equal to * percent (*%) of the royalties received by the
Company or its Affiliate from sales by any sublicensee of Licensed Products or
Licensed Processes. In addition, the Company shall pay to the Licensor *
percent (*%) of all sublicensing fees or other lump sum payments or other
compensation received by the Company or an Affiliate from its sublicensees for
the use, lease or sale of Licensed Products and Licensed Processes; provided,
however, that the Company shall pay to the Licensor * percent (*%) of lump sum
payments, if any, that are made within six (6) months from the Execution of this
Agreement and received by the Company or its Affiliate; provided
* This material has been omitted pursuant to a request for confidential
treatment. The material has been filed with the Securities and Exchange
Commission.
10
<PAGE>
further, however, that no amounts shall be due and payable to the Licensor
pursuant to this paragraph 4.1.2 on account of (a) payments made to the
Company solely for bona fide research and development (but which shall not
include option or other similar fees/consideration for access to or rights to
the Patent Rights or Know-how and (b) purchases of debt or equity securities
of the Company.
4.2 On sales of Licensed Products by the Company to Affiliates
or related parties which are end users of such Licensed Products the value of
Net Sales attributed under this Article 4 shall be that which would have been
received in an arms-length transaction, based on sales of like quantity and
quality products at or about the time of such transaction.
4.3 No multiple royalties shall be payable because the use,
lease or sale of any Licensed Product or Licensed Process is, or shall be,
covered by more than one valid and unexpired claim contained in the Patent
Rights. In addition, royalties shall be paid for a Licensed Product or
Licensed Process based upon only one of paragraphs 4.1.1 or 4.1.2 above (that
is, royalties on direct sales of a Licensed Product or Licensed Process by
the Company or its Affiliates shall be based only on paragraph 4.1.1, while
royalties on sales of a Licensed Product or Licensed Process by the Company's
sublicensees shall be based only on paragraph 4.1.2, so as to avoid double
counting).
4.4 In the event that a Licensed Product is sold in the form of
a combination product containing one or more products or technologies which
are themselves not a Licensed Product, the Net Sales for such combination
product shall be calculated by multiplying the sales price of such
combination product by the fraction A/(A+B) where A is the invoice price of
the Licensed Product or the Fair Market Value of the Licensed Product if sold
to an Affiliate and B is the total
11
<PAGE>
invoice price of the other products or technologies or the Fair Market Value of
the other products or technologies if purchased from an Affiliate. In the case
of a combination product which includes one or more Licensed Products, the Net
Sales for such combination product upon which the royalty due to the Licensor is
based shall not be less than the normal aggregate Net Sales for such Licensed
Product.
4.5 Royalty payments shall be paid in United States dollars in
New York, New York or at such other place as the Licensor may reasonably
designate consistent with the laws and regulations controlling in any foreign
country. Any withholding taxes which the Company, its Affiliate or any
sublicensee shall be required by law to withhold on remittance of the royalty
payments shall be deducted from such royalty payment to the Licensor. The
Company shall furnish the Licensor with the original copies of all official
receipts for such taxes. If any currency conversion shall be required in
connection with the payment of royalties hereunder, such conversion shall be
made by using the exchange rate prevailing at Citibank, N.A. in New York, New
York on the last business day of the calendar quarterly reporting period to
which such royalty payments relate.
4.6 Royalties payable to the Licensor shall be paid quarterly
within sixty (60) days from the end of the fiscal quarter. Each such payment
shall be for unpaid royalties which accrued within or prior to the Company's
two most recently completed fiscal quarters.
12
<PAGE>
4.7 Subject to the terms of this paragraph 4.7, the Company
shall pay to the Licensor a non-refundable minimum annual royalty (the
"Minimum Annual Royalty") equal to * dollars ($*) per year.
4.7.1 The Minimum Annual Royalty shall be fully creditable
against (a) any payments owing to the Licensor by the Company on account of any
payments due and owing under this Article 4, which payments are earned by the
Licensor in such year; (b) any payments in such year paid or payable under any
CRADA and (c) any payments in such year paid or payable on account of Sponsored
Research with any of the Co-owners.
4.7.2 Such minimum annual royalties shall be payable in
accordance with paragraph 5.1. Notwithstanding the provisions of the above
paragraph 4.6, any payment required to be made to the Licensor to meet the
Minimum Annual Royalty owed shall be due and payable within sixty (60) days from
the end of each calendar year.
4.7.3 Notwithstanding anything else to the contrary, in the
event that the Company is not granted access to the N.C.I. Clinical Data and
pre-clinical data owned by N.I.H. relating to potential Licensed Products and
Licensed Processes, then no Minimum Annual Royalty shall be due or payable to
the Licensor until the calendar year in which the first Phase II clinical trial
pursuant to a Company sponsored IND has commenced, thereafter, the Minimum
Annual Royalty shall be reduced to * dollars ($*) until the First Commercial
Sale.
* This material has been omitted pursuant to a request for confidential
treatment. The material has been filed with the Securities and Exchange
Commission.
13
<PAGE>
4.8 The Company shall pay to the Licensor the following
milestone payments which shall be credited against or deducted from royalties
otherwise owed or which may in the future be owing payable to the Licensor on
account of sublicensing royalties and/or lump sum payments received by the
Company or its Affiliate from sublicensees pursuant to paragraph 4.1.2:
4.8.1 * dollars ($*) as an up-front licensing fee, payable
upon the earlier to occur of (a) receipt by the Company of the N.C.I.
Clinical Data and pre-clinical data or (b) the date that is six (6) months
from the Effective Date, in accordance with paragraph 5.1. Any shares of
Common Stock (as defined below) issued to the Licensor in satisfaction of the
payment due pursuant to this paragraph 4.8.1 shall be priced at the closing
price per share of the Common Stock for the ten (10) consecutive trading days
preceding (i) the execution of this Agreement and (ii) the date on which
payment is made, whichever is lower;
4.8.2 * dollars ($*) upon approval of the first Company
sponsored IND for any Licensed Product with the United States Food and Drug
Administration (FDA) or its foreign equivalent, payable in accordance with
paragraph 5.1;
4.8.3 * dollars ($*) upon the date of initiation of the first
Company sponsored Phase III Clinical Trial in the United States for a Licensed
Product, payable in accordance with paragraph 5.1;
* This material has been omitted pursuant to a request for confidential
treatment. The material has been filed with the Securities and Exchange
Commission.
14
<PAGE>
4.8.4 * dollars ($*) upon the filing of the first Company
sponsored New Drug Application ("NDA") for a Licensed Product with the United
States FDA or its foreign equivalent, payable in accordance with paragraph 5.1;
and
4.8.5 * dollars ($*) upon the first final approval of a
Company sponsored NDA for a Licensed Product by the United States FDA or its
equivalent in any Foreign Major Market Country, payable in accordance with
paragraph 5.1.
4.9 Notwithstanding anything in this Agreement to the contrary,
no payment obligations shall be due with respect to any sale or sublicense
covering any Licensed Product or Licensed Process in a country if:
4.9.1 There are no issued Patent Rights underlying such
Licensed Product in such country; or
4.9.2 To the extent that a patent application is pending,
there is no claim within such patent application on which a royalty herein can
reasonably be based which has been pending for less than seven (7) years since
the initial filing date.
4.10 To the extent that the Company or any Affiliate of the
Company is required, by order or judgement of any court to obtain in any
jurisdiction any license from a third party in order to practice the rights
purported to be granted to the Company by the Licensor hereunder under issued
patents in such jurisdiction, then up to * percent (*%) of the royalties
payable under such license in such jurisdiction may be deducted from
royalties otherwise payable to the Licensor hereunder,
* This material has been omitted pursuant to a request for confidential
treatment. The material has been filed with the Securities and Exchange
Commission.
15
<PAGE>
provided that in no event shall the aggregate royalties payable to the
Licensor in any semi-annual period in such jurisdiction be reduced by more
than * percent (*%) as a result of any such deduction, provided further that
any excess deduction remaining as a result of such limitation may be carried
forward to subsequent periods.
4.11 For a period of three (3) years from the date of execution
of this Agreement the Company agrees to use its reasonable efforts to supply
up to ten thousand dollars ($10,000) worth of O(6) Benzyl guanine to the
N.C.I. at the Company's expense and calculated at the Company's cost. Any
requirements of O(6) Benzyl guanine on the part of the N.C.I. in excess of
such amount shall be provided to the N.C.I. by the Company at the Company's
cost. The Company's obligation to supply O(6) Benzyl guanine to the N.C.I.
shall terminate upon the earlier to occur of (a) five (5) years from the date
of execution of this Agreement, (b) termination of this Agreement pursuant to
Article 8 or (c) the establishment of a CRADA, which shall supersede this
paragraph 4.11.
ARTICLE 5 - PAYMENT BY EQUITY
5.1 The Company shall have the right, but not the obligation,
to fulfill a portion of its payment obligations pursuant to paragraphs 4.7
and 4.8 through the issuance of a number of shares of common stock of the
Company (the "Common Stock") equal to the cash value of such payments;
provided, however, that in no event shall the cash portion of any such
payments be less than the lesser of (a) * percent (*%) of the amount due and
owing and (b) * dollars ($*).
* This material has been omitted pursuant to a request for confidential
treatment. The material has been filed with the Securities and Exchange
Commission.
16
<PAGE>
5.2 For purposes of calculating the cash value of the Common
Stock under this Article 5, the current market price of the Common Stock
shall be deemed to be the average closing price of the Common Stock on the
ten (10) consecutive trading days prior to (a) the date of achievement of any
such milestone or (b) the date on which any payment pursuant to Article 4 is
due, whichever is earlier, on the principal national securities exchange on
which the Common Stock is admitted to trading or listed, or if not listed or
admitted to trading on any such exchange, the representative average closing
bid price of the Common Stock as reported by the National Association of
Securities Dealers, Inc. Automated Quotations System ("NASDAQ"), or other
similar organization if NASDAQ is no longer reporting such information, or,
if the Common Stock is not reported on NASDAQ, the average per share bid
price for the Common Stock in the over-the-counter market as reported by the
National Quotation Bureau or similar organization, or if not so available,
the fair market price of the Common Stock as determined by an independent
third party accounting firm selected by the Company.
5.3.1 All certificates representing the Stock and, until such
time as the Stock is sold in an offering which is registered under the
Securities Act or the Corporation shall have received an opinion of counsel
(including counsel for any recipient of stock hereunder) that such registration
is not required in connection with a resale (or subsequent resale) of the Stock
under all applicable laws, regulations and rules, all certificates issued in
transfer thereof or substitution therefor, shall, where applicable, have
endorsed thereon the following (or substantially equivalent) legends:
(a) THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN
ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR ANY STATE SECURITIES
17
<PAGE>
LAW. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH
REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL STATING
THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS
DELIVERY REQUIREMENTS OF SAID ACT UNDER ALL APPLICABLE LAWS, RULES AND
REGULATIONS OR IS OTHERWISE IN COMPLIANCE WITH ALL APPLICABLE LAWS AND
REGULATIONS.
(b) Any legend required to be placed thereon by any applicable
state securities law.
(c) A legend to the effect that such shares of stock are subject
to a License Agreement that limits the transferability of the shares under
certain conditions and applies to any transferee of such shares.
5.3.2 With a view to making available to the Licensor the
benefits of certain rules and regulations of the SEC which at any time permit
the sale of the Common Stock to the public without registration, the Company
shall use its reasonable efforts to:
(a) make and keep public information available, as those terms
are understood and defined in Rule 144 under the Act, at all times;
(b) file with the SEC in a timely manner all reports and other
documents required of the Company under the Securities Exchange Act of 1934 (the
"Exchange Act"); and
(c) so long as the Licensor owns any unregistered Registrable
Securities, furnish to the Licensor upon any reasonable request a written
statement by the Company as to its compliance with Rule 144 under the Act, and
of the Exchange Act, a copy of the most recent annual or quarterly report of the
Company, and such other reports and documents of the Company as the Licensor may
reasonably request in availing itself of any rule or regulation of the
Commission allowing the Licensor to sell any such securities without
registration.
18
<PAGE>
5.3.3 If the Common Stock is or becomes tradeable pursuant to
Rule 144 or a similar exemption from registration then the Licensor shall have
no right to the registration rights described in paragraph 5.5.
5.4 The Company agrees that if, at any time, and from time to
time, during the period commencing two (2) years after the date hereof, or
one (1) year after the Company's next public offering of Common Stock
registered under the Securities Act of 1933 (the "Act"), whichever is later,
and ending on the date which is five (5) years from the date hereof, the
Board of Directors of the Company shall authorize the filing of a
registration statement under the Act (other than the initial public offering
of the Company's Common Stock, or other than a registration statement on Form
S-8, Form S-4 or any other form which does not include substantially the same
information as would be required in a form for the general registration of
securities) in connection with the proposed offer of any of its securities by
it or any of its stockholders, the Company will, subject to the limitations
set forth in paragraph 5.5 below, (i) promptly notify the Licensor that such
registration statement will be filed and that the Common Stock then held by
the Licensor will be included in such registration statement at the
Co-owner's request, (ii) cause such registration statement to cover all of
such Common Stock issued to the Licensor requesting inclusion, (iii) use its
reasonable best efforts to cause such registration statement to become
effective as soon as practicable and (iv) take all other action necessary
under any Federal or state law or regulation of any governmental authority to
permit all such Common Stock which has been issued to the Licensor to be sold
or otherwise disposed of, and will maintain such compliance with each such
Federal and state law and regulation of any
19
<PAGE>
governmental authority for the period necessary for the Licensor to effect
the proposed sale or other disposition.
5.4.1 The Licensor shall only twice have the right to request
inclusion of any of their shares of Common Stock in a registration statement as
described in paragraph 5.1.
5.5 Notwithstanding paragraph 5.4 above, the Company may at any
time, abandon or delay any registration commenced by the Company. In the
event of such an abandonment by the Company, the Company shall not be
required to continue registration of shares requested by the Licensor for
inclusion and the Licensor shall retain the right to request inclusion of
shares pursuant to paragraph 5.4.
5.6 The Common Stock will be acquired by the Co-owners and/or
their designees for investment purposes only, for an indefinite period of
time, for their own account, not as a nominee or agent for any other Entity
(as defined in paragraph 1.2.2), and not with a view to the sale or
distribution of all or any part thereof, and the Co-owners have no present
intention of selling, granting any participation in, or otherwise
distributing, any or all of the Common Stock.
5.6.1 The Co-owners shall provide to the Company a list of
names of individuals and/or entities at least thirty (30) days prior to any
sale, grant of participation in or other distribution of any Common Stock by the
Licensor. Any sale, grant of participation in or other distribution of any
Common Stock by any of the Co-owners shall comply in all respects with the
Securities Act and the Exchange Act.
5.7 The parties agree to execute such further instruments and
to take such further action as may reasonably be necessary to carry out the
intent of this Article 5, and the Licensor
20
<PAGE>
specifically agrees to cooperate affirmatively with the Company, to the
extent reasonably requested by the Company, to enforce the rights of the
Company and its successors and assignees.
5.8 The Licensor agrees that, in connection with each
underwritten public offering registered under the Act of shares of Common
Stock or other equity securities of the Company by or on behalf of the
Company, they shall not sell, transfer or offer to sell or transfer, any
equity securities of the Company for such period (the "Lock-up Period") as
the managing underwriter of such offering determines is necessary to effect
the underwritten public offering; provided, however, that the Licensor shall
not be subject to a Lock-up Period greater than that required of the
Company's officers and directors. The Licensor further agrees that it will
sign an agreement as requested by the managing underwriter of such offering
to effect the foregoing.
5.9 With respect to any registration statement pursuant to
which the Licensor participates as a selling shareholder, to the extent
permitted by law, the Company shall indemnify the Licensor and each person
controlling the Licensor within the meaning of Section 15 of the Act, with
respect to which any registration, qualification or compliance has been
effected, against all claims, losses, damages and liabilities (or action in
respect thereof), including any of the foregoing incurred in settlement of
any litigation, commenced or threatened, arising out of or based on any
untrue statement (or alleged untrue statement) of a material fact contained
in any registration statement, prospectus or offering circular, or any
amendment or supplement thereof, incident to any such registration,
qualification or compliance, or based on any omission (or alleged omission)
to state therein a material fact required to be stated therein or necessary
to make the statements therein not misleading, in light of the circumstances
in which they were made, and will reimburse the Licensor,
21
<PAGE>
and each person controlling the Licensor, for legal and any other expenses
reasonably incurred in connection with investigating or defending any such
claim, loss, damage, liability or action as incurred; provided that the
Company will not be liable in any such case to the extent that any untrue
statement or omission or allegation thereof is made in reliance upon and in
conformity with written information furnished to the Company by or on behalf
of the Licensor and stated to be specifically for use in preparation of such
registration statement, prospectus or offering circular; provided that the
Company will not be liable in any such case where the claim, loss, damage or
liability arises out of or is related to the failure of the Licensor to
comply with the covenants and agreements contained in any agreement
respecting sales of securities of the Company, and except that the foregoing
indemnity agreement is subject to the condition that, insofar as it relates
to any such untrue statement or alleged untrue statement or omission or
alleged omission made in the preliminary prospectus but eliminated or
remedied in the amended prospectus on file with the Commission at the time
the registration statement becomes effective or in the amended prospectus
filed with the Commission pursuant to Rule 424(b) or in the prospectus
subject to completion and term sheet under Rule 434 of the Act, which
together meet the requirements of Section 10(a) of the Act (the "Final
Prospectus"), such indemnity agreement shall not inure to the benefit of any
the Licensor or person controlling the Licensor, if a copy of the Final
Prospectus furnished by the Company to the Licensor for delivery was not
furnished to the person or entity asserting the loss, liability, claim or
damage at or prior to the time such furnishing is required by the Act and the
Final Prospectus would have cured the defect giving rise to such loss,
liability, claim or damage.
22
<PAGE>
5.10 The Licensor will severally, if the Common Stock held by
the Licensor are included in the securities as to which such registration,
qualification or compliance is being effected, indemnify the Company, each of
its directors and officers, each underwriter and each person who controls the
Company within the meaning of Section 15 of the Securities Act, against all
claims, losses, damages and liabilities (or actions in respect thereof),
including any of the foregoing incurred in settlement of any litigation,
commenced or threatened, arising out of or based on any untrue statement (or
alleged untrue statement) of a material fact contained in any registration
statement, prospectus or offering circular, or any amendment or supplement
thereof, incident to any such registration, qualification or compliance, or
based on any omission (or alleged omission) to state therein a material fact
required to be stated therein or necessary to make the statements therein not
misleading, in light of the circumstances in which they were made, and will
reimburse the Company, such directors and officers, each underwriter and each
person controlling the Company for reasonable legal and any other expenses
reasonably incurred in connection with investigating or defending any such
claim, loss, damage, liability or action as incurred, in each case to the
extent, but only to the extent, that such untrue statement or omission or
allegation thereof is made in reliance upon and in conformity with written
information furnished to the Company by or on behalf of the Licensor and
stated to be specifically for use in preparation of such registration
statement, prospectus or offering circular; provided that the indemnity shall
not apply to the extent that such claim, loss, damage or liability results
from the fact that a current copy of the prospectus was not made available to
the Licensor and such current copy of the prospectus would have cured the
defect giving rise to such loss, claim, damage or liability.
23
<PAGE>
ARTICLE 6 - REPORTS AND RECORDS
6.1 The Company shall keep full, true and accurate books of
account containing all particulars that may be necessary for the purpose of
showing the amounts payable to the Licensor by way of royalty as aforesaid.
After First Commercial Sale, the Licensor may conduct an audit of the books
of account of the Company by the Licensor's internal audit division and/or by
another designated auditor selected by the Licensor, except one to whom the
Company has reasonable and material objection at the sole cost of the
Licensor at least once per year upon reasonable notice to the Company and at
a mutually agreeable time. In the event that an inspection shows an under
reporting or underpayment in excess of the greater of (a) fifty thousand
dollars ($50,000) and (b) five percent (5%) of royalties payable for any
twelve (12) month period, then the Company shall reimburse the Licensor for
the cost of the inspection at the time the Company pays the unreported
royalties. In addition, the Company shall conduct an independent audit of
sales and royalties at least every three (3) years if annual sales of
Licensed Products or Licensed Processes exceeds ten million dollars
($10,000,000). The audit shall address, at a minimum, the amount of gross
sales by or on behalf of the Company during the audit period, the amount of
funds owed to the Licensor under this Agreement and whether the amount owed
has been paid to the Licensor and is reflected in the records of the Company.
A report by the auditor shall be submitted to the Licensor promptly upon
completion. The cost of such audit shall be borne by the Company.
6.2 Within sixty (60) days from the end of each quarter of each
calendar year, the Company shall deliver to the Licensor complete and accurate
reports, giving such particulars of the
24
<PAGE>
business conducted by the Company during the preceding quarter under this
License Agreement as shall be pertinent to a royalty accounting hereunder.
These shall include at least the following:
6.2.1 All Licensed Products and Licensed Processes used,
leased or sold, by or for the Company or its Affiliates.
6.2.2 Total amounts invoiced for Licensed Products and
Licensed Processes used, leased or sold, by or for the Company or its
Affiliates.
6.2.3 Deductions applicable in computed "Net Sales" as
defined in Paragraph 1.7.
6.2.4 Total royalties due based on Net Sales by or for the
Company or its Affiliates.
6.2.5 Names and addresses of all sublicensees and Affiliates
of the Company.
6.2.6 On an annual basis, the Company's year-end financial
statements.
6.3 With each such quarterly report submitted, the Company
shall pay to the Licensor the royalties due and payable under this Agreement.
If no royalties shall be due, the Company shall not be required to make a
report pursuant to this Article 6.
6.4 Amounts which are not paid when due and which are not the
subject of a bona fide dispute shall accrue interest from the due date until
paid, at a rate equal to then prevailing prime rate of Citibank, N.A., plus
two percent (2%).
6.5 The Company agrees to forward to the Licensor annually a
copy of any report, which is in substance similar to the report required by
this Article 6, received from any sublicensee
25
<PAGE>
and other documents received from any sublicensee as the Licensor may
reasonably request, as may be pertinent to an accounting of royalties.
6.6 Attached hereto as Exhibit A is a Draft Development Plan
for O(6) Benzyl guanine and Related Technologies, to which the Company agrees
to use its reasonable efforts to adhere.
6.7 The Licensor agrees to hold in confidence each report
delivered by the Company pursuant to this Article 6. Notwithstanding the
foregoing, the Licensor may disclose any such information required to be
disclosed pursuant to any judicial, administrative or governmental request,
subpoena, requirement or order, provided that the Licensor takes reasonable
steps to provide the Company with the opportunity to contest such request,
subpoena, requirement or order.
ARTICLE 7 - PATENT PROSECUTION AND MAINTENANCE
7.1 Upon receipt of appropriate documentation of expenses, the
Company shall pay to the Licensor the approximate amount of * dollars ($*),
payable over a six (6) month period upon the earlier to occur of (a) receipt
by the Company of the N.C.I. Clinical Data and pre-clinical data or (b) the
date that is six (6) months from the Effective Date, for all reasonable
out-of-pocket expenses that the Licensor has incurred in connection with the
preparation, filing, prosecution and maintenance of the Patent Rights prior
to the execution of this Agreement. Subject to the provisions of Article 7.3
hereof, the Company shall continue to reimburse the Licensor for all such
future
* This material has been omitted pursuant to a request for confidential
treatment. The material has been filed with the Securities and Exchange
Commission.
26
<PAGE>
reasonable out-of-pocket expenses within sixty (60) days from receipt
by the Company of appropriate documentation of such expenses by the Licensor.
7.2 The Licensor shall diligently prosecute and maintain the
Patent Rights as set forth in Appendix I hereto (as the same may be amended
or supplemented from time to time after the date hereof), including, but not
limited to, the filing of patent applications which may be required or
desirable pursuant to and/or arising out of Sponsored Research, utilizing
Pennie & Edmond as patent counsel or such other patent counsel in the future
which may be mutually agreed upon by the parties hereto. The Licensor agrees
to keep the Company well informed with respect to the status and progress of
any such applications, prosecutions and maintenance activities and to consult
in good faith with the Company and take into account the Company's comments
and requests with respect thereto. Both parties agree to provide reasonable
cooperation to each other to facilitate the application and prosecution of
patents pursuant to this Agreement or arising out of any Sponsored Research.
7.3 The Licensor may, in its discretion, elect to abandon any
patent applications or issued patent comprising the Patent Rights, in which
case the Company shall have no further royalty obligation to the Licensor in
respect of any Licensed Products and Licensed Processes the manufacture, use
or sale of which are covered by an issued claim of such abandoned Patent
Rights. Prior to any such abandonment, the Licensor shall give the Company
at least sixty (60) days notice and a reasonable opportunity to take over
prosecution of such Patent Rights. In such event, the Company shall have the
right, but not the obligation, to commence or continue such prosecution and
to maintain any such Patent Rights under its own control and at its expense
and the Company shall then have no royalty or other obligation to the
Licensor in respect of any Licensed Products and
27
<PAGE>
Licensed Processes, the manufacture, use or sale of which is covered by an
issued claim of such Patent Rights. The Licensor agrees to cooperate in such
activities including execution of any assignments or other documents
necessary to enable the Company to obtain and retain sole ownership and
control of such Patent Rights.
ARTICLE 8 - TERMINATION
8.1 If the Company shall become bankrupt, or shall file a
petition in bankruptcy, or if the business of the Company shall be placed in
the hands of a receiver, assignee or trustee for the benefit of creditors,
whether by the voluntary act of the Company or otherwise, this License
Agreement shall automatically terminate.
8.2 Should the Company fail to make payment to the Licensor of
royalties due in accordance with the terms of this Agreement which are not
the subject of a bona fide dispute between the Licensor and the Company, the
Licensor shall have the right to terminate this License Agreement within
sixty (60) days after giving said notice of termination unless the Company
shall pay to the Licensor, within the 60-day period, all such royalties due
and payable. Subject to Article 9, upon the expiration of the 60-day period,
if the Company shall not have paid all such royalties due and payable, the
rights, privileges and license granted hereunder shall, at the option of the
Licensor, immediately terminate.
8.3 Upon any material breach or default of this License
Agreement by the Company, other than as set forth in Paragraphs 8.1 and 8.2
hereinabove, the Licensor shall have the right to terminate this Agreement
and the rights, privileges and license granted hereunder upon giving
28
<PAGE>
sixty (60) days notice to the Company. Such grounds for termination include,
but shall not be limited to, the Licensor's reasonable determination that the
Company is not using its reasonable best efforts to keep Licensed Products or
Licensed Processes reasonably available to the public after commercial use
commences. Subject to Article 9, such termination shall become effective
immediately unless the Company shall have cured any such breach or default
prior to the expiration of the sixty (60) day period referred to above.
8.4 The Company shall have the right at any time to terminate
this Agreement in whole or as to any portion of the Patent Rights by giving
ninety (90) days notice thereof in writing to the Licensor.
8.5 Upon termination of this Agreement for any reason, nothing
herein shall be construed to release either party from any obligation that
matured prior to the effective date of such termination or obligations under
Articles 6, 9, 10, 11, 16 and 17. Notwithstanding the foregoing, if this
Agreement is terminated by the Company prior to the date that is six (6)
months from the date hereof, the Company shall have no obligation to make any
payment under this Agreement whatsoever, except that the Company shall be
required to pay fifty percent (50%) of the license fee set forth in section
4.8.1. The Company and/or any sublicensee thereof may, however, after the
effective date of such termination and continuing for a period not to exceed
six (6) months thereafter, sell all completed Licensed Products, as well as
any Licensed Products in the process of manufacture at the time of such
termination, provided that the Company shall pay or cause to be paid to the
Licensor the royalties thereon as required by Article 4 of this License
Agreement and shall submit the reports required by Article 6 hereof on the
sales of Licensed Products.
29
<PAGE>
8.6 If not terminated sooner, this Agreement shall terminate on
the date of the last to expire claim contained in the Patent Rights.
8.7 Paragraph 4.11 shall survive termination of this Agreement
for a period of two (2) years from the date of termination unless this
Agreement is terminated as a result of a breach by any of the Co-owners or
failure of the Licensed Products to prove efficacious.
ARTICLE 9 - ARBITRATION
9.1 Any dispute or any controversy between the parties
involving the construction or application of any terms, covenants or
conditions of this Agreement, or transactions under it or any claim arising
out of or relating to this Agreement, shall be submitted to binding
arbitration. The parties shall first use good faith efforts to resolve any
such dispute through full and meaningful discussions, which shall include at
least one face-to-face meeting between authorized representatives of each
party and a written exchange of positions. If, after ninety (90) days from
the date of first discussion of the disputed issues, the parties are unable
to resolve the dispute, either party may refer the dispute, controversy or
claim to arbitration in New York, New York in accordance with the provisions
set forth below and the Commercial Arbitration Rules of the American
Arbitration Association (the "AAA") then in effect. Judgement upon the award
rendered by the arbitrators may be entered in any court having jurisdiction
thereof. Notwithstanding anything to the contrary which may now or hereafter
be contained in said rules of the AAA, the parties hereby agree as follows:
9.1.1 Each party shall appoint one (1) person to hear and
determine the dispute on or before the end of the sixtieth (60th) day after
receipt of notice of arbitration from the noticing
30
<PAGE>
party, and who shall have reviewed and agreed to terms of this clause.
Within thirty (30) days therefrom, the two persons so chosen shall select a
third, impartial arbitrator and the majority decision of the tribunal shall
be final and conclusive upon both parties. All such arbitrators shall be
experienced in the field related to the Agreement. If either party fails to
designate its arbitrator within the time period set forth above, then the
arbitrator designated by the one party shall act as the sole arbitrator and
shall be deemed to be the single, mutually approved arbitrator to resolve
the controversy. If the two selected arbitrators fail to agree upon the
identity of a third, said third arbitrator shall be selected by the AAA upon
application of either party thereto. If the parties are unable to agree upon
a rate of compensation for the arbitrators, they shall be compensated for
their services at a rate to be determined by the AAA.
9.1.2 Discovery shall be governed by the Federal Rules of Civil
Procedure. The scope and extent thereof shall be as the arbitrators determine
to be appropriate under the circumstances. The arbitrators shall issue a ruling
within thirty (30) days of impanelment setting forth the scope and extent of
discovery, and the date when all discovery is to be concluded. Although the
arbitrators shall have the duty to meet with the parties at least once in order
to hear evidence, the panel shall avail itself of all available technologies,
including conference calling and video conferencing, to resolve pre-hearing
and/or discovery matters.
9.1.3 The arbitrators shall have the power and authority to award
relief under legal or equitable principles, including interim or preliminary
relief.
9.1.4 The costs of the arbitration (excluding attorney's fees)
shall be borne by the non-prevailing party.
31
<PAGE>
9.1.5 The arbitrators shall have the right to direct the payment
of attorney's fees in their sole discretion.
9.2 Within one-hundred-eighty (180) days of the date of impanelment
(the date on which the third arbitrator agrees to serve, or the date on which
one of the parties fails to designate an arbitrator), the arbitrators shall,
upon the request of either party, issue a draft of a factual detailed,
reasoned written opinion of their findings of fact and conclusions of law.
Upon receipt by the requesting party of said written opinion, said requesting
party shall have the right within twenty (20) days to file a Motion to
Reconsider, and the arbitrators thereupon shall reconsider the issues raised
by said motion and either confirm or modify their decision. In any event,
the arbitrators shall then issue a Final Decision which shall then be final
and conclusive upon bot parties hereto.
ARTICLE 10 - INFRINGEMENT AND OTHER ACTIONS
10.1 The Company and the Licensor shall promptly provide written
notice, to the other party, of any alleged infringement by a third party of the
Patent Rights and provide such other party with any available evidence of such
infringement.
10.2 During the term of this Agreement, the Company shall have the
right, but not the obligation, to prosecute and/or defend, at its own expense
and utilizing counsel of its choice, any infringement of, and/or challenge to,
the Patent Rights. In furtherance of such right, the Licensor hereby agrees
that the Company may join the Licensor as a party in any such suit, without
expense to the Licensor. No settlement, consent judgment or other voluntary
final disposition of any such suit which would adversely affect the rights of
the Licensor may be entered into without the consent of
32
<PAGE>
the Licensor, which consent shall not be unreasonably withheld. The Company
shall indemnify and hold the Licensor harmless against any costs, expenses or
liability that may be found or assessed against the Licensor in any such suit
other than resulting from the Licensor's negligence or wilful misconduct.
10.3 In the event that a claim or suit is asserted or brought
against the Company alleging that the manufacture or sale of any Licensed
Product by the Company, an Affiliate of the Company, or any sublicensee, or
the use of such Licensed Product by any customer of any of the foregoing,
infringes proprietary rights of a third party, the Company shall give written
notice thereof to the Licensor. The Company may, in its sole discretion,
modify such Licensed Product to avoid such infringement and/or may settle on
terms that it deems advisable in its sole discretion, subject to paragraph
10.2. Otherwise, the Company shall have the right, but not the obligation,
to defend any such claim or suit. In the event the Company elects not to
defend such suit, the Licensor shall have the right, but not the obligation
to do so at its sole expense.
10.4 Any recovery of damages by the Company, in any such suit,
shall be applied first in satisfaction of any unreimbursed expenses and legal
fees of the Company relating to the suit and then to the Licensor for any
royalties credited in accordance with paragraph 10.5. The balance remaining
from any such recovery shall be treated as royalties received by the Company
from sublicensees and shared by the Licensor and the Company in accordance
with Paragraph 4.1.2 hereof.
10.5 The Company may credit up to fifty percent (50%) of any
litigation costs incurred by the Company in any country pursuant to this
Article 10 and up to 50% of all amounts paid in judgement or settlement of
litigation pursuant to this Article 10 against royalties thereafter
33
<PAGE>
payable to the Licensor hereunder for such country and apply the same toward
one-half of its actual, reasonable out-of-pocket litigation costs. If
one-half of such litigation costs in such country exceeds 50% of royalties
payable to the Licensor in any year in which such costs are incurred than the
amount of such costs, expenses and amounts paid in judgement or settlement,
in excess of such 50% of the royalties payable shall be carried over and
credited against royalty payments in future years for such country.
10.6 If within six (6) months after receiving notice of any
alleged infringement, the Company shall have been unsuccessful in persuading
the alleged infringer to desist, or shall not have brought and shall not be
diligently prosecuting an infringement action, or if the Company shall notify
the Licensor, at any time prior thereto, of its intention not to bring suit
against the alleged infringer, then, and in those events only, the Licensor
shall have the right, but not the obligation, to prosecute, at its own
expense and utilizing counsel of its choice, any infringement of the Patent
Rights, and the Licensor may, for such purposes, join the Company as a party
plaintiff. The total cost of any such infringement action commenced solely
by the Licensor shall be borne by the Licensor and the Licensor shall keep
any recovery or damages for infringement or otherwise derived therefrom and
such shall not be applicable to any royalty obligation of the Company.
10.7 In any suit to enforce and/or defend the Patent Rights
pursuant to this License Agreement, the party not in control of such suit
shall, at the request and expense of the controlling party, cooperate in all
respects and, to the extent possible, have its employees testify when
requested and make available relevant records, papers, information, samples,
specimens, and the like.
34
<PAGE>
ARTICLE 11 - LIMITATION OF LIABILITY, INDEMNITY
11.1 The Licensor, by this License Agreement, makes no
representations or warranties as to the validity and/or breadth of the
inventions contained in the Patent Rights and the Company so acknowledges.
The Licensor, by this License Agreement makes no representations or
warranties as to patents now held or which will be held by others in the
field of the Licensed Products and/or Licensed Processes for a particular
purpose.
11.2 EXCEPT AS MAY BE EXPRESSLY PROVIDED HEREIN, THE LICENSOR
DOES NOT MAKE, AND EXPRESSLY DISCLAIMS ANY WARRANTIES, EITHER EXPRESS OR
IMPLIED, ORAL OR WRITTEN, AS TO ANY MATTER WHATSOEVER, INCLUDING
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
11.3 The Company agrees to defend, indemnify and hold the
Licensor harmless from and against all liability, demands, damages, including
without limitation, expenses or losses including death, personal injury,
illness or property damage arising directly or indirectly (a) out of use by
the Company or its transferees of inventions licensed or information
furnished under this License Agreement or (b) out of any use, sale or other
disposition by the Company or its transferees of Patent Rights, Licensed
Products or Licensed Processes, in each case which are not judicially
determined to be the result of Licensor's negligence or wilful misconduct.
The Company agrees that any sublicense agreement it enters relative to the
Licensed Products and/or Licensed Processes shall contain a covenant by such
sub-licensee providing for the indemnification of the Licensor as provided in
this Article.
35
<PAGE>
11.4 Prior to the First Commercial Sale, the Company shall
obtain and maintain products liability insurance covering the risk of claim,
liabilities, expenses and judgments for which it has agreed to indemnify the
Licensor pursuant to paragraph 11.3 hereof. Coverage shall be in an amount
which is not less than one million dollars ($1,000,000) per occurrence. The
parties agree that adequate evidence of the required coverage has or will be
provided by the Company to the Licensor at: Penn State Intellectual Property
Office, 113 Technology Center, University Park, PA 16802-7000, and the
Company agrees to keep said office informed of any changes in coverage or
carriers.
ARTICLE 12 - ASSIGNMENT
This Agreement and the rights and duties appertaining hereto may not
be assigned by either party without first obtaining (a) the written consent of
the other, which consent shall not be unreasonably withheld and (b) the approval
of the N.I.H., which shall not be unreasonably withheld. Any such purported
assignment, without the written consent of the other party and the N.I.H., shall
be null and of no effect. Notwithstanding the foregoing, the Company may assign
this Agreement without the consent of the Licensor (i) to a purchaser, merging
or consolidating corporation, or acquiror of substantially all of the Company's
assets or business and/or pursuant to any reorganization qualifying under
section 368 of the Internal Revenue Code of 1986 as amended, as may be in effect
at such time in an arm's-length transaction approved by the Board of Directors
in accordance with applicable law, provided that the surviving entity of such
purchase, merger, consolidation, acquisition or reorganization is a publicly
traded company and agrees to abide by the terms of this Agreement,
36
<PAGE>
or (ii) to an Affiliate of the Company, provided that such Affiliate is a
publicly traded company and/or the Company agrees to continue to satisfy all
payment obligations owed to the Licensor hereunder.
ARTICLE 13 - PAYMENT OF FEES AND EXPENSES
Each of the Company and the Licensor shall be responsible for their
own expenses relating to the preparation and consummation of this Agreement and
the agreements and transactions contemplated hereby.
ARTICLE 14 - USE OF NAMES AND PUBLICATION
14.1 Nothing contained in this Agreement shall be construed as
granting any right to the Company or its Affiliates to use in advertising,
publicity, or other promotional activities any name, trade name, trademark,
or other designation of the Licensor or any of its units (including
contraction, abbreviation or simulation of any of the foregoing) without the
prior, written consent of the Licensor; provided, however, that the Licensor
acknowledges and agrees that the Company may use the name of the Licensor and
the names of the Principal Investigators in various documents used by the
Company for capital raising and financing without such prior written consent
but only to the extent that such use of names may be reasonably required by
law. The Licensor acknowledges that the Principal Investigators may act as
consultants and scientific advisors to the Company with respect to the
licenses granted to the Company hereunder, subject to the respective policies
of the Licensor.
14.2 Nothing herein shall be deemed to establish a relationship
of principal and agent between the Licensor and the Company, nor any of their
agents or employees for any purpose
37
<PAGE>
whatsoever. This Agreement shall not be construed as creating a partnership
between the Licensor and the Company, or as creating any other form of legal
association or arrangement which would impose liability upon one party for
the act or failure to act of the other party.
14.3 Except as set forth in paragraph 14.4, in the event that
the Licensor or Principal Investigators desire, individually or as a group,
to publish or disclose, by written, oral or other presentation, Know-how,
Patent Rights, or any material information related thereto then the Licensor
or the Principal Investigator(s) shall notify the Company in writing by
facsimile where confirmed by the receiving party, and/or by certified or
registered mail (return receipt requested) of their intention at least sixty
(60) days prior to any speech, lecture or other oral presentation and at
least sixty (60) days before any written or other publication or disclosure.
The Principal Investigator(s) shall include with such notice a description of
any proposed oral presentation or, in any proposed written or other
disclosure, a current draft of such proposed disclosure or abstract. No
later than thirty (30) days following the receipt of such notice, the Company
may request that the Principal Investigator(s) and the Licensor, delay such
presentation, publication or disclosure for a reasonable period of time in
order to enable the Company to file, or have filed on their behalf, a patent
application, copyright or other appropriate form of intellectual property
protection related to the information to be disclosed or request that the
Licensor do so. Upon receipt of such request to delay such presentation,
publication or disclosure, the Licensor and the Principal Investigator(s)
shall arrange for a delay of such presentation, publication or disclosure for
a reasonable period of time necessary for the Company or the Licensor to
file, or have filed on its behalf, such patent application, copyright or
other appropriate form of intellectual property protection in form and in
substance
38
<PAGE>
reasonably satisfactory to the Company and the Licensor; provided, however,
that in no event shall such delay be greater than forty-five (45) days. If
neither the Principal Investigator(s) nor the Licensor receive any such
request from the Company to delay such presentation, publication or
disclosure, the Licensor or the Principal Investigator(s) may submit such
material for presentation, publication or other form of disclosure.
14.4 In the event that the N.I.H., or the Principal
Investigator(s) of the N.I.H. (the "N.I.H. Investigator(s)"), desires,
individually or as a group, to publish or disclose, by written, oral or other
presentation, Know-how, Patent Rights, or any material information related
thereto then the N.I.H. or the N.I.H. Investigator(s) shall notify the
Company in writing by facsimile where confirmed by the receiving party,
and/or by certified or registered mail (return receipt requested) of their
intention at least thirty (30) days prior to any speech, lecture or other
oral presentation and at least thirty (30) days before any written or other
publication or disclosure. The N.I.H. Investigator(s) shall include with
such notice a description of any proposed oral presentation or, in any
proposed written or other disclosure, a current draft of such proposed
disclosure or abstract. No later than thirty (30) days following the receipt
of such notice, the Company may request that the N.I.H. and the N.I.H.
Investigator(s), delay such presentation, publication or disclosure for an
additional period of thirty (30) days (which 30-day period shall not be
renewable) in order to enable the Company to file, or have filed on their
behalf, a patent application, copyright or other appropriate form of
intellectual property protection related to the information to be disclosed
or request that the N.I.H. do so. Upon receipt of such request to delay such
presentation, publication or disclosure, the N.I.H. and the N.I.H.
Investigator(s) shall arrange for a second thirty (30) day period of delay of
such presentation,
39
<PAGE>
publication or disclosure so that the Company or the N.I.H. may file, or have
filed on its behalf, such patent application, copyright or other appropriate
form of intellectual property protection in form and in substance reasonably
satisfactory to the Company and the N.I.H. If neither the N.I.H. nor the
N.I.H. Investigator(s) receive any such request from the Company to delay
such presentation, publication or disclosure, the N.I.H. or the N.I.H.
Investigator(s) may submit such material for presentation, publication or
other form of disclosure.
ARTICLE 15 - PAYMENTS, NOTICES AND OTHER COMMUNICATIONS
Any payment, notice or other communication required or permitted to be
given pursuant to this Agreement shall be in writing and sent by certified first
class mail, postage prepaid, by hand delivery or by facsimile if confirmed in
writing, in each case effective upon receipt, at the addresses below or as
otherwise designated by written notice given to the other party:
In the case of the Licensor:
416 Old Main
University Park, PA 16802
Attn: David E. Branigan
Associate Treasurer
Tel: 814-865-1359
Fax:
With a copy to:
N.I.H.: 6011 Executive Boulevard, Ste. 325
Rockville, MD 20852
Attn: Joseph Contrera and
Linda Harris
Tel: 301-496-7057 Ext. 244
Fax: 301-402-0220
40
<PAGE>
Case Western:
Office of the Provost
Case Western Reserve University
10900 Euclid Avenue
Cleveland, OH 44106-7004
Attn: University Attorney
Tel: 216-368-4388
Fax: 216-368-4325
In the case of the Company:
Pacific Pharmaceuticals, Inc.
6730 Mesa Ridge Road
San Diego, CA 92121
Attn: Dr. H. Laurence Shaw
Tel: 619-550-3900
Fax: 619-550-3929
With a copy to:
Paramount Capital Investments, LLC
787 Seventh Avenue
New York, NY 10019
Attn: Michael S. Weiss
Tel: 212-554-4350
Fax: 212-554-4355
ARTICLE 16 - CONFIDENTIALITY
16.1 Any proprietary or confidential information directly relating to
the Invention (including but not limited to Know-how and patent prosecution
documents relating to Patent Rights) collectively constitute the "Confidential
Information." The Company and the Licensor agree that they will not use the
Confidential Information for any purpose unrelated to this Agreement or any
Sponsored Research, and will hold it in confidence during the term of this
41
<PAGE>
Agreement and for a period of five (5) years after the termination or expiration
date of this Agreement. The Company shall exercise with respect to such the
Confidential Information the same degree of care as the Company exercises with
respect to its own confidential or proprietary information of a similar nature,
and shall not disclose it or permit its disclosure to any third party (except to
those of its employees, consultants, or agents who are bound by the same
obligation of confidentiality as the Company is bound by pursuant to this
Agreement). However, such undertaking of confidentiality by the Company shall
not apply to any information or data which:
16.1.1 The Company receives at any time from a third-party
lawfully in possession of same and having the right to disclose same.
16.1.2 Is, as of the date of this Agreement, in the public
domain, or subsequently enters the public domain through no fault of the
Company.
16.1.3 Is independently developed by the Company as
demonstrated by written evidence without reference to information disclosed to
the Company by the Licensor.
16.1.4 Is disclosed pursuant to the prior written approval of
the Licensor.
16.1.5 Is required to be disclosed pursuant to law or legal
process (including, without limitation, to a governmental authority) provided,
in the case of disclosure pursuant to legal process, reasonable notice of the
impending disclosure is provided to the Licensor and the Licensor has agreed to
such disclosure in writing or have exhausted their right to contest such
disclosure.
42
<PAGE>
ARTICLE 17 - MISCELLANEOUS PROVISIONS
17.1 This License Agreement shall be construed, governed,
interpreted and applied in accordance with the laws of the State of New York,
without regard to principles of conflicts of laws.
17.2 If this Agreement or any associated transaction is
required by the law of any nation to be either approved or registered with
any governmental agency, the Company shall assume all legal obligations to do
so and the costs in connection therewith.
17.3 The Company shall observe all applicable United States and
foreign laws with respect to the transfer of Licensed Products and related
technical data to foreign countries, including, without limitation, the
International Traffic in Arms Regulations (ITAR) and the Export
Administration Regulations.
17.4 The parties hereto acknowledge that this Agreement,
including the Appendices and documents incorporated by reference, sets forth
the entire agreement and understanding of the parties hereto as to the
subject matter hereof, and shall not be subject to any change of modification
except by the execution of a written instrument subscribed to by the parties
hereto.
17.5 The provisions of this License Agreement are severable,
and in the event that any provision of this License Agreement shall be
determined to be invalid or unenforceable under any controlling body of law,
such invalidity or unenforceability shall not in any way affect the validity
or enforceability of the remaining provisions hereof.
43
<PAGE>
17.6 The failure of either party to assert a right hereunder or
to insist upon compliance with any term or condition of this License
Agreement shall not constitute a waiver of that right or excuse a similar
subsequent failure to perform any such term or condition by the other party.
17.7 The headings of the several articles are inserted for
convenience of reference only and are not intended to be a part of or to
affect the meaning or interpretation of this Agreement.
17.8 This Agreement will not be binding upon the parties until
it has been signed below on behalf of each party, in which event, it shall be
effective as of the date recited on page one.
17.9 This Agreement may be executed in two or more counterparts
each of which shall be deemed an original, but all of which shall together
constitute one and the same instrument.
17.10 This Agreement embodies the entire understanding of the
parties relating to the licensing of the Invention and shall supersede all
previous communications, representations or understandings, either oral or
written, between the parties relating to the subject matter hereof.
17.11 Each party hereto shall be excused from any breach of
this Agreement which is proximately caused by governmental regulation, act of
war, strike, act of God or other similar circumstance normally deemed outside
the control of the parties.
44
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this License
Agreement, in triplicate by proper persons thereunto duly authorized.
PACIFIC PHARMACEUTICALS, INC. PENNSYLVANIA STATE
UNIVERSITY
By: /s/ Dr. H. Laurence Shaw By: /s/ David Branigan
-------------------------------- ----------------------------------
Name: Dr. H. Laurence Shaw Name: David Branigan
------------------------------ --------------------------------
Title: Chief Executive Officer Title: Associate Treasurer
----------------------------- -------------------------------
Date: March 18, 1998 Date: March 13, 1998
----------------------------- -------------------------------
AGREED AND ACCEPTED:
UNIVERSITY OF CHICAGO CASE WESTERN RESERVE UNIVERSITY
By: /s/ Mary Ellen Sheridan By:
-------------------------------- ----------------------------------
Name: Mary Ellen Sheridan Name:
------------------------------ --------------------------------
Title: Assistant Vice President Title:
----------------------------- -------------------------------
Date: March 17, 1998 Date:
----------------------------- -------------------------------
NATIONAL INSTITUTES OF HEALTH
By: /s/ Joe Contrera
--------------------------------
Name: Joe Contrera
------------------------------
Title: Office of Technology Transfer
-----------------------------
Date: March 12, 1998
-----------------------------
45
<PAGE>
APPENDIX I
U.S. Patent #'s 5,091,430, 5,358,952, 5,352,669, 5,525,606 and U.S. Patent
Application # 08/620/969, filed on March 25, 1996, U.S. Patent Application #
08/255/190, filed on June 7, 1994 and Divisional U.S. Patent Application #
08/661/923, filed on June 11, 1996 (divisional of U.S. Patent #5,525,606).
46
<PAGE>
SCHEDULE A
47
<PAGE>
EXHIBIT A
DRAFT PLAN FOR THE DEVELOPMENT OF O(6)-BENZYL GUANINE
AND RELATED TECHNOLOGIES
The following will serve to outline Pacific Pharmaceuticals, Inc.'s (the
"Company") plans for development of O(6)-Benzyl guanine ("BG") and related
technologies as an intervenous chemotherapeutic agent used in combination with
alkylating agents such as BCNU (the "Agent" or "Agents") for the treatment of
cancer.
The Company intends to establish a clinical development plan in order to
obtain regulatory approval of BG from the United States Food and Drug
Administration as well as from equivalent foreign regulatory authorities on a
world-wide basis. It is anticipated that with the information currently
available from completed pre-clinical and clinical studies conducted by the
National Institute of Health, the Cancer Therapy Evaluation Program ("CTEP"),
the National Cancer Institute and various universities, the Company will be able
to commence Phase II clinical trials.
The Company believes that the continued participation of CTEP will be
ensured through the execution of a Cooperative Research and Development
Agreement ("CRADA") to be negotiated by and between the Company and CTEP. The
Phase II study may involve therapy with a combination of BG and an Agent in
previously untreated cancer patients or in patients who have failed therapy with
an Agent.
The Company will study the benefits of development of selected related
technologies through Sponsored Research Agreements or other means. Related
technologies of potential
48
<PAGE>
interest to the Company may include 8-oxo-BG, certain ribosylated derivatives
with increased water solubility, and gene therapy approaches to protecting
the bone marrow from toxicity.
The Company and /or its Affiliates agree to use their reasonable best
efforts to attain the following milestones for its performance under this
agreement and, within sixty (60) days of achieving a milestone, shall notify the
Co-owners that such milestone has been achieved.
For the O(6) Benzylguanine parent molecule:
- -------------------------------------------------------------------------------
EVENT DATE
- -------------------------------------------------------------------------------
First filing of a Company
Sponsored Investigational New
Dug Application with the
United States Food and Drug
Administration (FDA) or
foreign equivalent in a Major *
Market Country
- -------------------------------------------------------------------------------
Completion of enrollment of
the first Company Sponsored
Phase II clinical trial with
the FDA or its foreign
equivalent in a Major Market
Country *
- -------------------------------------------------------------------------------
Completion of enrollment of
the first Company Sponsored
Phase III clinical trial with
the FDA or its foreign
equivalent in a Major Market
Country *
- -------------------------------------------------------------------------------
First filing of a Product
License Application or foreign
equivalent in a Major Market
Country *
- -------------------------------------------------------------------------------
First receipt of Approvable
Letter by the FDA or foreign
equivalent in a Major Market
Country *
- -------------------------------------------------------------------------------
* This material has been omitted pursuant to a request for confidential
treatment. The material has been filed with the Securities and Exchange
Commission.
49
<PAGE>
It is understood and agreed by the Co-owners that in the event that the Company
is not provided with the N.C.I. Clinical Data and pre-clinical data, then each
of the above milestones shall be extended by three (3) years.
For additional candidate compounds, if any, the Company and/or its
Affiliates agree to use reasonable best efforts to proceed with pre-clinical
development within four (4) years. If after that time, the Company and/or its
Affiliates have not commenced pre-clinical development, the Company and/or its
Affiliates will give due consideration to granting a sublicense to companies
interested in developing any such additional candidate compounds.
50
<PAGE>
EXHIBIT B
51
<PAGE>
Exhibit 10.59
INTRODUCTION AGREEMENT
Pursuant to this Introduction Agreement (this "Agreement") entered into as
of February 12, 1998 (the "Effective Date"), between Paramount Capital
Investments, LLC, having a place of business at 787 Seventh Avenue, 48th floor,
New York, New York 10019 (the "Disclosing Party") and Pacific Pharmaceuticals,
Inc. (the "Recipient"), the parties hereto agree:
1. The Disclosing Party will introduce Recipient to the persons,
universities and/or companies (each an "Introduced Party") listed on Schedule I
with the intent that Recipient may acquire the technologies and companies
described thereon being developed by such parties (the "Acquisition
Candidates").
2. In the event that the Recipient enters into a contract,
license, stock purchase agreement, loan agreement or any other agreement or
arrangement with respect to any of the Acquisition Candidates, then the
Recipient shall pay to the Disclosing Party for each such Acquisition
Candidate a total of $*, of which payment of $* is due upon signing of an
agreement for an Acquisition Candidate and $* shall be deferred until *.
Additionally, Recipient shall grant to the Disclosing Pary and/or its
designees a number of shares of common stock of the Company, par value $.002
per share, vesting according to Schedule II attached hereto. In addition,
upon receipt of appropriate documentation, the Recipient shall reimburse the
Disclosing Party for all reasonable expenses incurred in connection with any
Acquisition Candidate not to exceed $*. For a period of thirty-six (36)
months from the date hereof, Recipient shall not enter into a contract,
license, stock purchase agreement, loan agreement or other agreement or
arrangement with any Introduced Party unless the compensation as set forth
herein is paid to the Disclosing Party.
3. It is agreed that the compensation to Disclosing Party with
respect to the Acquisition Candidates shall be solely the obligation of
Recipient.
4. Recipient recognizes and understands that the Disclosing Party
has not executed any agreements (other than the Confidentiality Agreement as
described below and attached hereto as Exhibit A) with respect to the proposed
Acquisition Candidates and therefore Recipient agrees not to contact any such
parties or any of their officers, directors, employees, agents, affiliates
and/or consultants without an officer of the Disclosing Party or without the
prior written consent of an officer of the Disclosing Party and further agrees
not to take any action that would adversely affect or otherwise hinder the
Disclosing Party's ability to ultimately execute any agreements with such
parties.
5. This Agreement constitutes the entire agreement of the parties
pertaining to the subject matter hereof, and the parties have made no
agreements, representations or warranties relating to the subject matter of this
Agreement that are not set forth herein and no agreement subsequent to the date
hereof relating to the subject matter of this Agreement shall be binding upon
either party unless in writing and executed by both the Disclosing Party and
Recipient.
6. Neither party shall be reasonable in relying on oral statements
made by the other which are not contained in a written agreement signed by both
parties.
* This material has been omitted pursuant to a request for confidential
treatment. The material has been filed with the Securities and Exchange
Commission.
<PAGE>
This Agreement may not be modified, amended or waived in any manner except by
an instrument in writing signed by each of the parties hereto.
7. The waiver by either party of compliance with any provision of
this Agreement by the other party shall not operate or be construed as a waiver
of such party of a provision of this Agreement.
8. Neither party may assign its rights or obligations hereunder.
9. This Agreement shall be governed by and construed in accordance
with the laws of the State of New York, without regard to the conflicts of the
law principles thereof.
10. Any disputes between the parties hereto arising out of this
Agreement and the transactions contemplated hereby shall be determined by valid
and binding arbitration in New York, New York.
11. This Agreement may be executed in any number of counterparts,
each of which counterparts, when so executed and delivered, shall be deemed an
original, and all of which counterparts, taken together, shall constitute one
and the same instrument.
12. Any notice or other communication under this Agreement shall be
in writing and shall be deemed to have been given: when delivered personally
against receipt therefor; one (1) day after being sent by Federal Express or
similar overnight delivery; or three (3) days after being mailed registered or
certified mail, postage prepaid, return receipt requested, to either party at
the address set forth below, or to such other address as such party shall give
by notice hereunder to the other party.
If to Recipient: Pacific Pharmaceuticals, Inc.
6730 Mesa Ridge Road
San Diego, CA 92121
Attn: Chief Executive Officer
Tel: 619-550-3900
Fax: 619-550-3929
If to Disclosing Party: Paramount Capital Investments, LLC
787 Seventh Avenue
New York, New York 10019
Attn: Michael S. Weiss
Tel: 212-554-4350
Fax: 212-554-4355
2
<PAGE>
IN WITNESS WHEREOF, the parties hereto have caused this Agreement of
Introduction to be executed by their respective duly authorized representatives
as of the day and year first written above.
PARAMOUNT CAPITAL INVESTMENTS, LLC
by
---------------------------------
Name: Lindsay A. Rosenwald, M.D.
Title: Chairman
PACIFIC PHARMACEUTICALS, INC.
by
---------------------------------
Name: H. Laurence Shaw
Title: President and Chief Executive Officer
3
<PAGE>
SCHEDULE I
INTRODUCED PARTIES AND ACQUISITION CANDIDATES
1. Name: Dr. Anthony Pegg
Dr. Robert Moschel
Company/University: Penn State University
University of Chicago
National Institute of Health
Technology: 0-6-Benzyl Guanine
License Agreement: U.S. Patent #'s: 5,091,430,
5,358,952, 5,352,669, 5,525,606 and
their foreign equivalents and any
patent applications and patents
issuing from any of the foregoing.
U.S. Patent Application #'s:
08/620/969 filed 3/25/96, 08/255/190
filed on 6/7/94, 08/661/923 filed on
6/11/96 and their foreign
equivalents, and any patents
applications and patents issuing from
any of the foregoing.
<PAGE>
SCHEDULE II
EQUITY COMPENSATION
The following represents the equity compensation to the Disclosing Party for
assigning the licensing and/or acquisition opportunities described in
Schedule I to this Introduction Agreement.
* shares vesting pursuant to the following schedule until 100% of the shares are
vested:
- --------------------------------------------------------------------------------
Vesting Event Vesting Shares
- --------------------------------------------------------------------------------
Upon the execution of Definitive
Agreements with respect to such
Acquisition Candidates *%
- --------------------------------------------------------------------------------
Upon the initiation of the first
Company Sponsored Phase I
clinical trial or equivalent (if no phase I,
then upon the entry into Phase II) *%
- --------------------------------------------------------------------------------
Upon the initiation of the first
Company Sponsored Phase II
clinical trial or equivalent (including
a continuation of a Phase I into a
Phase II, or a trial designated a Phase I/II) *%
- --------------------------------------------------------------------------------
Upon the initiation of EACH
subsequent Company Sponsored
Phase II clinical trial or equivalent
(including a continuation of a Phase I
into a Phase II, or a trial designated a
Phase I/II) for an additional indication *%
- --------------------------------------------------------------------------------
Upon the initiation of THE FIRST
Company Sponsored Phase III
clinical trial or equivalent (including a
continuation of a Phase II into a Phase III,
or a trial designated a Phase II/III) *%
- --------------------------------------------------------------------------------
Upon the initiation of EACH
subsequent Company Sponsored
Phase III clinical trial or equivalent
(including a continuation of a Phase II into
a Phase III, or a trial designated a
Phase II/III) for an additional indication *%(1)
- --------------------------------------------------------------------------------
Upon EACH NDA or foreign filing
in a Foreign Major Market *%
- --------------------------------------------------------------------------------
Upon EACH NDA or equivalent
approval in a Foreign Major Market *%
- --------------------------------------------------------------------------------
- ---------------------
(1) For the sake of clarity, the parties hereto agree that if additional
indications are sought for the Technology in addition to the first indication
(currently anticipated to be glioma) then early vesting is provided through
these additional vesting events.
* This material has been omitted pursuant to a request for confidential
treatment. The material has been filed with the Securities and Exchange
Commission.
<PAGE>
Exhibit 99.60
Contact: Linda B. Preucil (AMEX) PHA
Director of Business Relations WWW.PACIFICPHARM.COM
908/ 497-0160
[email protected]
- ------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
PACIFIC PHARMACEUTICALS LICENSES CHEMOSENSITIZER FOR CANCER
- - RELATED COMPOUNDS AND TECHNOLOGIES TO OVERCOME CANCER DRUG RESISTANCE -
SAN DIEGO, CA, March 23, 1998 - Pacific Pharmaceuticals, Inc. today announced
a worldwide exclusive license for O(6) Benzyl Guanine (BG) and a series of
related compounds and technologies which enhance the effectiveness of a class
of currently used chemotherapeutic agents (O(6) alkylators). Multiple Phase
I human clinical trials conducted at the University of Chicago, Duke
University Medical Center and Case Western Reserve University are nearing
completion in different cancer types, including brain, colon and renal
carcinoma. These technologies are licensed to Pacific from Pennsylvania
State University on behalf of itself, National Institutes of Health and other
universities.
Pre-clinical animal data show that treatment with BG results in increased
survival and heightens the anti-tumor activity of chemotherapeutic agents.
The Company's collaborators believe that BG works by inactivating the DNA
repair protein AGT (O(6) alkylguanine-DNA alkyltransferase) present in tumor
cells and known to be a significant source of resistance to treatment with
0(6) alkylating agents. Studies led by Pugh Scholar Dr. Anthony E. Pegg and
his team have shown a correlation between low levels of the repair protein
AGT in tumors and enhanced responsiveness to treatment.
"O(6) Benzylguanine has the potential to enhance the activity of O(6)
alkylating agents in drug resistant cancers. This is particularly exciting
because cancer resistance to these alkylating agents has been a major problem
for their efficacy," commented Dr. David Golde, Physician-in-Chief, Sloan
Kettering Cancer Center and Chairman of Pacific's Scientific Advisory Board.
"This novel class of compounds has the potential to expand the indications
for O(6) alkylating agents to other cancers," stated H. Laurence Shaw, M.D.,
Chairman, President and Chief Executive Officer. Pacific Pharmaceuticals,
Inc. is actively engaged in the development of cancer therapies, and is
preparing to enter Phase I/II human clinical trials this year with its
proprietary photodynamic therapy compound BOPP for the treatment of brain
cancer, and a proprietary Cancer Immunotherapy for the treatment of
metastatic breast cancer. The Company manages products through pre-clinical,
clinical development and regulatory approval to position them for successful
commercialization.
<PAGE>
The terms of the license agreement include payments for royalties, license
fees and milestone payments to be paid in cash or common stock of the
Company. Paramount Capital Investments, LLC ("Paramount") acted as financial
advisor to the Company in connection with the identification, negotiation and
consummation of the license and will receive a fee in cash and securities
vesting upon achievement of certain performance based events. Paramount is
affiliated with certain significant shareholders and a Director of the
Company.
THIS NEWS RELEASE CONTAINS FORWARD LOOKING STATEMENTS. THE ACTUAL RESULTS
COULD VARY FROM THOSE EXPECTED DUE TO A VARIETY OF RISKS SET FORTH FROM TIME
TO TIME IN THE COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION,
INCLUDING THE COMPANY'S REGISTRATION STATEMENT ON FORM S-3, AS DECLARED
EFFECTIVE ON SEPTEMBER 4, 1997. THE COMPANY UNDERTAKES NO OBLIGATION TO
PUBLICLY RELEASE THE RESULTS OF ANY OF THESE FORWARD LOOKING STATEMENTS WHICH
MAY BE MADE TO REFLECT EVENTS OR CIRCUMSTANCES AFTER THE DATE HEREOF OR TO
REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
2
